Following a Q2 which marked a new record level for the company, Redsense has during the months of July and August 2019 already received orders from the US with a total value surpassing MSEK 4. Larger US providers have publically communicated their intention to continue to improve and increase their operations in home hemodialysis. This is also in line with the US Government’s new initiative to promote home hemodialysis.
“We are happy to see a continued increase in the use of Redsense in the US, and we are expecting more orders during the fall. There is a trend among dialysis providers to move more towards home hemodialysis, which opens interesting opportunities for Redsense Medical”, says Patrik Byhmer, CEO, Redsense Medical AB.